Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster
Artificial intelligence developer Anthropic has acquired Mithril Medicine, a stealth startup operated by a single pseudonymous developer who used the Claude AI model to coordinate multiple laboratories and pursue treatments for rare muscular dystrophies. The July transaction provides Anthropic with internal rare-disease drug programs and expands its footprint in the life sciences sector. Alongside the startup purchase, Anthropic disclosed collaborations with several external life sciences partners utilizing its AI technology for tasks including antibody design and clinical trial planning.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Anthropic acquired Mithril Medicine, a one-person startup developing treatments for two rare forms of muscular dystrophy.
- ✓ Cody Tranbarger revealed himself as the pseudonymous Twitter poster Professor Oak following the company acquisition.
- ✓ Anthropic is working with Bristol Myers Squibb, BigHat Biosciences and four other partners to use Claude for research tasks.
What changed
Anthropic publicly disclosed its acquisition of Mithril Medicine alongside a list of six industry partners applying Claude to drug discovery.
Live updates
-
Anthropic Buys One-Person Biotech Mithril Medicine
Artificial intelligence developer Anthropic has acquired Mithril Medicine, a stealth startup operated by a single pseudonymous developer who used the Claude AI model to coordinate multiple laboratories and pursue treatments for rare muscular dystrophies. The July transaction provides Anthropic with internal rare-disease drug programs and expands its footprint in the life sciences sector. Alongside the startup purchase, Anthropic disclosed collaborations with several external life sciences partners utilizing its AI technology for tasks including antibody design and clinical trial planning.
Why it matters
The acquisition marks a concrete push by a major AI lab into proprietary drug development rather than solely providing software tools to external researchers. The startup was run by Cody Tranbarger under the pseudonym Professor Oak before the deal brought his solo operational model inside Anthropic. This development highlights how artificial intelligence systems are being leveraged by single operators to manage complex biological research across multiple facilities.
What is confirmed
- Anthropic acquired Mithril Medicine, a one-person startup developing treatments for two rare forms of muscular dystrophy.
- Cody Tranbarger revealed himself as the pseudonymous Twitter poster Professor Oak following the company acquisition.
- Anthropic is working with Bristol Myers Squibb, BigHat Biosciences and four other partners to use Claude for research tasks.
What to watch next
- Further announcements regarding how Anthropic integrates Mithril Medicine's rare muscular dystrophy programs into its internal operations.
- Updates on the progress of drug discovery partnerships between Anthropic and companies like Bristol Myers Squibb.
confidence 95%Sources used for this update (11)
- Endpoints News — Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster
- Anthropic — Early progress on accelerating drug development with Claude
- R&D World — Anthropic acquires a one-person biotech that used Claude to coordinate 11 labs
- Business Wire — Enveda Collaborates with Anthropic to Accelerate Drug Development
- The Information — Anthropic Buys a Small Drug Startup as It Pushes Deeper Into Biotech
- Interesting Engineering — Anthropic’s Claude designs 35,000 antibodies in one month to target food allergies
- NDTV — A One-Person Startup Just Got Bought By Anthropic
- www.fool.com — The Biggest Risk to Anthropic Stock Is the Company Itself
- www.theinformation.com — Anthropic Buys a Small Drug Startup as It Pushes Deeper Into ...
- www.aiaffairs.com — Anthropic buys one-person Mithril Medicine and names six drug ...
- www.indiatoday.in — One man used Claude to find cure for rare muscle diseases ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community